Two meta-analyses of the efficacy of reboxetine as an antidepressant demonstrated attempts to detect publication bias in clinical trials. Based on positive trial data, reboxetine was originally passed as a treatment for depression in many countries in Europe and the UK in 2001 (though in practice it is rarely used for this indication). A 2010 meta-analysis concluded that reboxetine was ineffective and that the preponderance of positive-outcome trials reflected publication bias, mostly due to trials published by the drug manufacturer Pfizer. A subsequent meta-analysis published in 2011, based on the original data, found flaws in the 2010 analyses and suggested that the data indicated reboxetine was effective in severe depression (see Reboxetine § Efficacy). Examples of publication bias are given by Ben Goldacre and Peter Wilmshurst.